Mirror Biologics, Inc.
Clinical trials sponsored by Mirror Biologics, Inc., explained in plain language.
-
Experimental combo for tough-to-treat colon cancer trial pulled before start
Disease control TerminatedThis study was designed for people with advanced colorectal cancer that had stopped responding to standard treatments. It aimed to test a combination of two experimental immunotherapies (AlloStim and an anti-PDL1 drug) to see if they could shrink tumors or help people live longer…
Phase: PHASE2 • Sponsor: Mirror Biologics, Inc. • Aim: Disease control
Last updated May 26, 2026 10:14 UTC
-
New immunotherapy shows promise in liver cancer fight
Disease control TerminatedThis study tests an experimental immunotherapy called AlloStim against standard treatments (Sorafenib, Lenvatinib, or FOLFOX4) in 150 Asian adults with advanced liver cancer. The main goal is to see if AlloStim helps people live longer. The study is currently suspended.
Phase: PHASE2, PHASE3 • Sponsor: Mirror Biologics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC